argenx SE · ARGX · FY2026 Q3 · Calendar Q4 2026
argenx: VYVGART momentum and a broader late-stage pipeline
The supplied analysis supports the view that sustained VYVGART demand and pipeline progress could underpin continued growth, but the thesis depends on clinical execution, regulatory progress, payer access and disciplined integration.
Earnings scorecard
Reported versus consensusMarket reaction
close-to-close (session unavailable)Ask FN2 about ARGX FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current analysis emphasizes continued VYVGART momentum, positive ALKIVIA data, additional late-stage pipeline milestones and the operational impact of the Forte acquisition.
Guidance delta
No new guidance was provided in the supplied analysis.
Key takeaways
- Management described continued VYVGART growth and ongoing label-expansion efforts.
- The pipeline is moving toward several late-stage readouts, filings and potential launches.
- The Forte acquisition adds pipeline breadth but also raises integration and expense-execution questions.
- The supplied analysis supports a constructive operating narrative, while regulatory and trial execution remain key tests.
Management priorities
- Advance VYVGART submissions and the planned auto-injector launch.
- Deliver empasiprubart and FB102 clinical milestones.
- Progress the diversified clinical pipeline and integrate the Forte acquisition.
Follow ARGX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationargenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates.…
Historical context
All ARGX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +1.8% | Quest Diagnostics raises outlook as volume and consumer health expand |
Latest beats and misses
Who reports nextBeat on EPS
- NSCFY2026 Q3 · October 22, 2026+4.6% EPS+3.1% move
- POOLFY2026 Q3 · October 22, 2026+1.2% EPS+14.4% move
- UNPFY2026 Q3 · October 22, 2026+1.7% EPS+3.6% move
- PGFY2027 Q1 · October 22, 2026+6.4% EPS+5.6% move
- CMCSAFY2026 Q3 · October 22, 2026+8.5% EPS+3.4% move
- CRSFY2027 Q1 · October 22, 2026+6.9% EPS-20.6% move
Missed on EPS
- PCGFY2026 Q3 · October 22, 2026-0.8% EPS-1.3% move
- PHMFY2026 Q3 · October 22, 2026-4.5% EPS+5.8% move
- HBANLFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
- BCSFY2026 Q3 · October 22, 2026-1.5% EPS-2.6% move
- SSBFY2026 Q3 · October 21, 2026-4.2% EPS+2.4% move
- ROLFY2026 Q3 · October 21, 2026-1.4% EPS+5.6% move
Get the ARGX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-23T06:03:37.348314+00:00
- FN2 earnings calendar · 2026-07-29T01:23:15.868211+00:00
- Polygon adjusted daily market bars · 2026-10-23T06:20:42.517416+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-23T06:20:42.513990+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-23. For educational purposes only; not investment advice.